| Completed | Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Ca NCT04164069 | Anne Noonan | Phase 1 |
| Unknown | The Role of Vitamin D in Predicting Response to Neoadjuvant Therapy in Patients With Rectal Cancer NCT04857203 | Istanbul Training and Research Hospital | — |
| Terminated | Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Can NCT04044430 | University of California, San Francisco | Phase 1 |
| Completed | Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer NCT03154190 | Stanford University | N/A |
| Completed | Low Glycemic Load Diet in Patients With Stage I-III Colon Cancer NCT02129218 | Case Comprehensive Cancer Center | N/A |
| Withdrawn | Laparoscopic Surgery or Robotic-Assisted Laparoscopic Surgery in Treating Patients With Rectal Cancer That Can NCT01196000 | City of Hope Medical Center | N/A |
| Completed | Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer NCT01191684 | City of Hope Medical Center | Phase 1 |
| Withdrawn | Altered Chemotherapy Sequencing During Neoadjuvant Therapy for Patients With Stage II or III Rectal Adenocarci NCT01302613 | University of Texas Southwestern Medical Center | Phase 1 / Phase 2 |
| Completed | RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors NCT01158274 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorecta NCT00551421 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Resveratrol in Treating Patients With Colorectal Cancer That Can Be Removed By Surgery NCT00433576 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer NCT00303628 | ECOG-ACRIN Cancer Research Group | Phase 3 |
| Completed | Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressi NCT00138177 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer NCT00134069 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidne NCT00101348 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer NCT00087191 | National Cancer Institute (NCI) | N/A |
| Terminated | Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent NCT00070122 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Bevacizumab, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II or Stage III NCT00052559 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer NCT00028496 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With NCT00025337 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Followed by Surgery in Treating Patients With L NCT00006094 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer NCT00005818 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu NCT00004074 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer NCT00019006 | National Cancer Institute (NCI) | Phase 1 |